ZANOPRIMA-LIFESCIENCES
11.10.2021 12:15:06 CEST | Business Wire | Press release
Zanoprima Lifesciences (www.zanoprima.com ) (https://www.linkedin.com/company/zanoprima/ ) a UK based company, announced commercial production of its high purity synthetic (S)-Nicotine (SyNic) using a revolutionary patented process that does not involve the use of tobacco or any synthetic racemic mixture.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005296/en/
This is a landmark development for the trillion-dollar tobacco industry and its 1.3 billion consumers as it heralds the arrival of a superior, substantially lower-risk, cost-effective, and greener alternative to a global industry that is arguably the single biggest avoidable cause of death globally.
Zanoprima has developed and patented the process to manufacture high purity (typically 99.9%), synthetic (S)-Nicotine (SyNic) for commercial use that is free of TSNA (tobacco-specific Nitrosamines), toxins, carcinogens, odour, and harsh taste. Zanoprima offers the entire range of products including SyNic (S)-Nicotine Bitartrate (Nicotine Bitartrate Dihydrate), SyNic (S)-Nicotine polacrilex resin/Nicotine resinate and its novel proprietary (S)-Nicotine complex.
SyNic (S)-Nicotine conforms to and exceeds European Pharmacopeia (EP) and United States Pharmacopeia (USP) specifications. “Green Chemistry” principles compliant production process minimizes the environmental impacts of nicotine production. Applications include:
SyNic Protonated (S)-Nicotine e-liquid for e-cigarettes is without any potentially harmful ingredients such as organic acids and propylene glycol. It is pure, stable and has a long shelf life. E-cigarettes that use SyNic offer a smooth taste and enhanced nicotine experience, a distinct advantage given the nicotine limit guidelines/rules in e-liquids in the EU and other geographies.
Znus: Tobacco-free white snus is completely sodium and tobacco free, delivering a smooth taste without the characteristic odour and harshness of natural nicotine. It has an instant burst followed by sustained release as desired by the traditional Snus users.
Next-gen chewing gum and lozenges that are sodium free offer unique characteristics, providing an instant burst and sustained release of nicotine that users seek. These gums and lozenges contain a new proprietary nicotine complex with superior bioavailability and taste.
Forthcoming launches: Tobacco free heated nicotine products unlike existing tobacco-based Heat Not Burn products and skin friendly transdermal patches for Alzheimer’s and dementia.
Global Patents: Zanoprima owns patent applications or registration for its revolutionary manufacturing process in all major geographies including United States, Europe, Great Britain, Australia, China, India, and others.
As a responsible synthetic nicotine (SyNic) manufacturer Zanoprima will distribute SyNic in strict compliance with regulations in each of its markets, globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005296/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches Digital Marketplace to Scale AI and Digital Innovation Across Energy15.6.2026 14:15:00 CEST | Press release
Curated marketplace connects energy professionals, developers and partners to discover, deploy and scale trusted AI agents, domain models and digital applications Global energy technology company SLB (NYSE: SLB) today announced the launch of the SLB Digital Marketplace, a curated digital destination designed to help energy companies rapidly discover and deploy specialized AI agents, domain models, skills, tools, data connectors and digital applications within their existing digital environments. The SLB Digital Marketplace extends the company’s open platform strategy to its Tela™ agentic AI assistant by enabling SLB, partners, independent software vendors (ISVs), developers and customers to bring purpose-built digital capabilities to the energy industry through a single, governed channel. All marketplace offerings are certified against SLB standards for security, interoperability and compatibility before listing. The launch comes as the industry moves toward agentic AI — where software
Thales at Eurosatory 2026: Ready today. Ready tomorrow15.6.2026 14:01:00 CEST | Press release
Thales pavilion (stand C247),Parc des Expositions, Paris Nord Villepinte, FranceMonday 15 to Friday 19 June, 2026. As Eurosatory 2026 opens its doors, Thales is pleased to share with you a complete overview of the announcements that will be made during the first day of this international defense and security show. This document centralises all our news, innovations and partnerships, released on June, 15th, 2026 with direct links to the associated press releases: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615204020/en/ Thales at Eurosatory 2026: Ready today. Ready tomorrow.Thales unveils new AI-powered training data analytics platform to enhance military training.Thales launches next-generation 70mm laser-guided rocket dedicated for counter-drone operations.Thales unveils next-generation Bushmaster Mulga Utility Variant.Thales launches RapidStriker, a complete system for protection against drones.Renault Group and Thal
Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery15.6.2026 14:00:00 CEST | Press release
Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory animal care and use. The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity, and operational excellence across its preclinical research and drug discovery activities. Biocytogen’s Boston facility serves as a key hub supporting the company’s expanding portfolio of drug discovery and translational research capabilities. The facility enables a broad range of in vivo studies supporting antibody therapeutics, multispecific antibodies, ADCs, cell therapies, and other innovative biologics programs for pharmaceutical and biotechnology partners worldwide. Through its proprietary BioMice™ platform, Biocytogen has established one of the industry’s most comprehensive collections of genetically engineered disease mo
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements15.6.2026 12:00:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission
KRM22 partners with Sigma AI to enhance market surveillance and risk intelligence capabilities15.6.2026 12:00:00 CEST | Press release
KRM22, the technology and software investment company focused on risk management solutions for capital markets, today announced a strategic partnership with Sigma AI, a leading provider of AI-driven financial insights, to integrate advanced news sentiment analytics into its risk management application suite. The integration marks a significant enhancement to KRM22’s capabilities, enabling clients to incorporate real-time market sentiment insights derived from global news sources directly into their risk frameworks. By leveraging Sigma AI’s proprietary natural language processing and machine learning models, KRM22 will help firms better identify emerging risks, anticipate market-moving events, and make more informed trading and compliance decisions. Advancing risk management through AI-driven sentiment analysis As part of the first phase of the collaboration, KRM22 will embed Sigma AI’s news sentiment engine within its application suite. This will provide users with actionable intellige
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
